Logo image
Back
Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer
Journal article   Peer reviewed

Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer

Athina Stravodimou and Ioannis A. Voutsadakis
International journal of breast cancer, Vol.2013(2013), pp.64-69
01/01/2013
DOI: 10.1155/2013/289563
PMCID: PMC3707237
PMID: 23864954

View Online

Abstract

Background. An elevated platelet count is often associated with malignancies, and it has been confirmed as an adverse prognostic factor in various cancers including early stage breast cancer. We sought to determine if thrombocytosis is also a prognostic factor in metastatic breast cancer. Patients and Methods. The records of 165 metastatic breast cancer patients with complete follow-up that had thrombocytosis or normal platelet counts were reviewed. Kaplan-Meier curves were constructed, and the survivals of the two groups were compared using the LogRank test. A Cox regression analysis was used to determine if thrombocytosis is an independent factor for overall and progression free survival. Results. There was a statistically significant difference in overall and progression free survival favoring the normal platelets group (LogRank test P=0.038 and 0.008, resp.). Thrombocytosis remained a significant adverse prognostic factor in multivariate analysis. Other independent prognostic factors for overall survival included age, ER/PR status, and grade. Conclusion. Thrombocytosis represents an independent adverse prognostic factor in patients with metastatic breast cancer. Thus metastatic breast cancer joins a range of cancers in which this easily measurable value can be used for clinical prognostication. Further use as a predictive value for specific treatments has a rationale and deserves to be investigated.

Details

Metrics

3 Record Views
39 Times Cited - Web of Science
Logo image